Mercurochrome was effectively banned in the United States because it contains mercury, and no manufacturer ever submitted safety data to prove it was safe for over-the-counter use. In 1998, the FDA reclassified merbromin (the active ingredient in Mercurochrome) as “not generally recognized as safe and effective,” making it illegal to sell without formal drug approval that no company pursued. The familiar red-orange liquid that millions of Americans once dabbed on scrapes and cuts disappeared from pharmacy shelves not because of a single dramatic safety scandal, but because of growing awareness that putting a mercury compound on broken skin carried real risks that safer alternatives didn’t.
What Mercurochrome Actually Contains
Mercurochrome is a brand name for merbromin, an organic mercury compound with the molecular formula C₂₀H₈Br₂HgNa₂O₆. Each molecule contains one atom of mercury bonded into an organic structure that also includes bromine and sodium. Mercury makes up roughly 25% of the compound’s weight. When the product was developed in 1918 by Hynson, Westcott and Dunning, a Baltimore pharmaceutical firm connected to the University of Maryland School of Pharmacy, the antiseptic properties of mercury were well known and its toxicity was poorly understood. For decades, Mercurochrome was considered a painless, effective way to clean minor wounds, and it became a household staple.
The FDA’s 1998 Decision
The FDA didn’t issue a sudden ban. Instead, the agency had been reviewing hundreds of over-the-counter drug ingredients since the 1970s, sorting them into categories: safe and effective (Category I), not safe or not effective (Category II), or insufficient data to decide (Category III). Merbromin landed in that third category, meaning there wasn’t enough evidence to confirm it was safe.
Manufacturers were given years to submit supporting data. None did. On April 22, 1998, the FDA published a final rule declaring that merbromin and dozens of other unproven ingredients were “not generally recognized as safe and effective for OTC use.” The rule took effect on October 19, 1998. From that point forward, any product containing merbromin sold over the counter would be considered misbranded and an unapproved new drug under federal law. A company could theoretically have pursued full new drug approval through the FDA’s standard process, but the cost of clinical trials for an old, inexpensive antiseptic made that commercially pointless, especially when mercury-free alternatives already dominated the market.
Why Mercury on Wounds Is Dangerous
The core safety concern is straightforward: mercury applied to broken skin gets absorbed into the body. For decades, doctors assumed that the small amounts in a dab of Mercurochrome stayed on the surface and posed no real threat. That assumption turned out to be wrong. Clinical evidence showed that merbromin is absorbed through burned, broken, or otherwise damaged skin, and in some cases the absorption was severe enough to cause organ failure and death.
The documented cases are sobering. In one report, a patient who had merbromin applied to a surgical wound developed mercury poisoning that progressed to aplastic anemia, a condition where the bone marrow stops producing enough blood cells. In another, a 37-year-old burn patient treated with a 2% merbromin solution over 50% of his body developed pink-colored urine within six days. He became restless, then confused, then slipped into a coma. He died on day 10 from respiratory arrest, with extremely high mercury concentrations in his urine.
Children face particular risk. Young children are more vulnerable to kidney damage from organic mercury compounds used as antiseptics. In one case, repeated application of merbromin to an infant’s omphalocele (a condition where abdominal organs protrude through the navel) led to kidney failure, respiratory arrest, and death. A separate case described a 10-day-old newborn who was accidentally given mercurochrome orally for seven days due to a misunderstanding of medical instructions. The infant lost appetite, failed to gain weight, and was found to have elevated blood mercury levels. That child survived after receiving chelation therapy, a treatment that binds mercury in the bloodstream so it can be excreted.
These cases involved large or prolonged exposures, not a single dab on a scraped knee. But the principle they demonstrated was clear: merbromin doesn’t just sit on the skin’s surface. It enters the body. And once mercury is circulating in the bloodstream, it can damage the kidneys, nervous system, and bone marrow. The FDA’s position was simple. With no data proving that typical consumer use was safe, and with evidence that absorption could be dangerous, there was no justification for keeping it on shelves.
Why No One Fought to Keep It
By the late 1990s, Mercurochrome had already been losing ground for years. Hydrogen peroxide, povidone-iodine (the brown liquid sold as Betadine), and antibiotic ointments had taken over the first-aid aisle. These products worked as well or better than merbromin at preventing wound infections, and none carried the risk of mercury exposure. The economics were plain: no pharmaceutical company was going to spend millions on clinical trials to rescue a cheap, decades-old product that consumers had already moved away from and that contained a known toxin.
Povidone-iodine became the most common direct replacement for general antiseptic use. It kills a broad range of bacteria and fungi, doesn’t contain heavy metals, and is still widely used in hospitals and homes. Antibiotic ointments containing ingredients like bacitracin or neomycin also filled the gap for minor cuts and scrapes. For most everyday wounds, clean water and a bandage are now considered sufficient by many medical guidelines, with antiseptics reserved for situations where infection risk is higher.
Availability Outside the United States
Mercurochrome is not universally banned worldwide. It remains widely available in parts of South America, Asia, and Africa, where it is still used as an inexpensive wound antiseptic. Some countries have followed the U.S. lead in restricting mercury-containing medical products, but many have not, particularly where regulatory infrastructure is less developed and affordable alternatives are harder to access. International health organizations have pushed to reduce mercury use in consumer products broadly, but merbromin continues to be sold in pharmacies in countries where it was never formally restricted.
If you grew up using Mercurochrome and wonder whether those childhood applications caused lasting harm, the answer for most people is no. A thin coat on a small scrape exposes the body to far less mercury than the clinical cases that raised alarm. The concern was always about the potential for serious harm in vulnerable situations: large wounds, repeated use, infants, burn patients. The FDA’s decision reflected a reasonable standard. When a product contains a toxic heavy metal and no one can prove it’s safe, it shouldn’t be sold next to the Band-Aids.